Adaptive Biotechnologies Corporation (MUN:1HM)
Germany · Delayed Price · Currency is EUR | Market Cap | 3.00B +96.1% |
| Revenue (ttm) | 256.21M +55.9% |
| Net Income | -43.09M |
| EPS | -0.28 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 18.68 |
| Previous Close | 18.68 |
| Day's Range | 18.68 - 18.68 |
| 52-Week Range | 9.44 - 18.68 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jul 29, 2026 |
About Adaptive Biotechnologies
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient’s body during and after treatment, known as Minima... [Read more]
Financial Performance
In 2025, Adaptive Biotechnologies's revenue was $276.98 million, an increase of 54.77% compared to the previous year's $178.96 million. Losses were -$59.50 million, -62.69% less than in 2024.
Financial numbers in USD Financial StatementsNews
Adaptive Biotechnologies price target raised to $25 from $21 at TD Cowen
TD Cowen analyst Dan Brennan raised the firm’s price target on Adaptive Biotechnologies (ADPT) to $25 from $21 and keeps a Buy rating on the shares. The firm adjusted targets…
Adaptive Biotechnologies to Report Second Quarter 2026 Financial Results on July 29, 2026
SEATTLE, July 09, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune syst...
Adaptive Biotechnologies price target raised to $20 from $18 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Adaptive Biotechnologies (ADPT) to $20 from $18 and keeps an Equal Weight rating on the shares. The firm is updating its model…
Adaptive Biotechnologies price target raised to $22 from $21 at Guggenheim
Guggenheim raised the firm’s price target on Adaptive Biotechnologies (ADPT) to $22 from $21 and keeps a Buy rating on the shares. The firm adjusted models and forecasts for select…
Adaptive Biotechnologies prices $300M convertible senior note offering
Adaptive Biotechnologies (ADPT) “announced the pricing of its offering of $300 million aggregate principal amount of 0% convertible senior notes due 2031 in a private offering to persons reasonably be...
Adaptive Biotechnologies Corporation Prices Upsized $300 Million Convertible Senior Notes Offering
Proceeds expected to be deployed to repay the OrbiMed Purchase Agreement to enhance financial flexibility Additional proceeds used to pay for the capped call with a premium of 100% and to repurchase $...
Adaptive Biotechnologies management to meet with Craig-Hallum
Meeting to be held in New York on June 18 hosted by Craig-Hallum.
Adaptive Biotechnologies offers to sell $250M in 2031 convertible senior notes
Last night, the company stated: “Adaptive Biotechnologies (ADPT) announced its intention to offer, subject to market and other conditions, $250 million aggregate principal amount of convertible senior...
Adaptive Biotechnologies plans separation of immune medicine platform
Adaptive Biotechnologies said on Monday it planned to separate its immune medicine business from its residual cancer-testing unit, as it reviews options for the drug-discovery business and focuses o...
Adaptive to plans to separate minimal residual disease, immune medicine segments
Adaptive Biotechnologies (ADPT) announced its intention to pursue a separation of its minimal residual disease and immune medicine businesses. The company is evaluating strategic and structural altern...
Adaptive Biotechnologies Announces Plan to Separate Its MRD and Immune Medicine Businesses
MRD has scaled into a profitable, category-leading MRD diagnostics business, while Immune Medicine has built a differentiated discovery platform powered by proprietary immune data and AI MRD has scale...
Adaptive Biotechnologies Corporation Announces Proposed Convertible Senior Notes Offering
Proceeds expected to be deployed to repay the OrbiMed Purchase Agreement to enhance financial flexibility Additional proceeds used to pay for the capped call with a premium of at least 75% and to repu...
Adaptive Biotechnologies Transcript: 46th Annual William Blair Growth Stock Conference
clonoSEQ continues to lead MRD testing with strong clinical and pharma adoption, driving revenue and margin growth. Expansion in blood-based testing, community settings, and EMR integration supports further market penetration. Immune Medicine advances data partnerships, with positive EBITDA and free cash flow targeted by end of 2026.
Adaptive Biotechnologies Slides: 46th Annual William Blair Growth Stock Conference
Adaptive Biotechnologies has posted slides in relation to its latest quarterly earnings report, which was published on June 3, 2026.
At ASCO and EHA 2026, New Data Reinforce the Pivotal Role of clonoSEQ® MRD Testing Across Hematology Clinical Practice and Research
Over 30 presentations at ASCO and EHA leverage clonoSEQ MRD testing to assess novel therapies and support MRD-guided patient care across blood cancers
Adaptive Biotechnologies to Participate in Upcoming Investor Conferences
SEATTLE, May 21, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial-stage biotechnology company that aims to translate the genetics of the adaptive immune syste...
Adaptive Biotechnologies price target lowered to $18 from $21 at Morgan Stanley
Morgan Stanley analyst Kallum Titchmarsh lowered the firm’s price target on Adaptive Biotechnologies (ADPT) to $18 from $21 and keeps an Equal Weight rating on the shares. Published first on…
Adaptive Biotechnologies price target lowered to $19 from $21 at JPMorgan
JPMorgan lowered the firm’s price target on Adaptive Biotechnologies (ADPT) to $19 from $21 and keeps an Overweight rating on the shares. The firm updated the company’s model post the…
Adaptive Biotechnologies price target raised to $21 from $19 at TD Cowen
TD Cowen raised the firm’s price target on Adaptive Biotechnologies (ADPT) to $21 from $19 and keeps a Buy rating on the shares. The firm said the company delivered another…
Adaptive Biotechnologies Earnings Call Transcript: Q1 2026
Q1 revenue grew 45% year-over-year, led by 53% MRD growth and record clinical volumes. Sequencing gross margin rose to 70%, and full-year MRD guidance was raised to $260M–$270M. Strong adoption, operational efficiency, and expanding pharma partnerships support continued momentum.
Adaptive Biotechnologies Earnings release: Q1 2026
Adaptive Biotechnologies released its Q1 2026 earnings on May 5, 2026, summarizing the period's financial results.
Adaptive Biotechnologies Slides: Q1 2026
Adaptive Biotechnologies has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 5, 2026.
Adaptive Biotechnologies Quarterly report: Q1 2026
Adaptive Biotechnologies has published its Q1 2026 quarterly earnings report on May 5, 2026.
Adaptive Biotechnologies Reports First Quarter 2026 Financial Results
SEATTLE, May 05, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics...
Adaptive Biotechnologies Proxy statement: Proxy filing
Adaptive Biotechnologies filed a proxy statement on April 24, 2026, providing details for shareholder voting and corporate governance matters.